Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection

Dermatol Ther. 2018 Jul;31(4):e12601. doi: 10.1111/dth.12601. Epub 2018 Apr 6.

Authors

Francesca Peccerillo¹, Giulia Odorici¹, Giovanni Pellacani¹, Andrea Conti¹

Affiliation

¹ Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.

PMID: 29633448
DOI: 10.1111/dth.12601

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Coinfection*
Dermatologic Agents / therapeutic use*
Hepatitis B / complications*
Hepatitis B / diagnosis
Hepatitis C / complications*
Hepatitis C / diagnosis
Humans
Male
Psoriasis / complications
Psoriasis / diagnosis
Psoriasis / drug therapy*
Severity of Illness Index
Skin / drug effects*
Skin / pathology
Treatment Outcome
Viral Load

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Dermatologic Agents
secukinumab